Abbott Laboratories

ABT remains in a Stage 2 advancing phase, with rising short-term EMAs and an active Parabola pattern signaling strong trend acceleration. Momentum is extreme overbought and price is approaching the 200-day SMA overhead, creating unfavorable timing conditions. Execution should be deferred, targeting disciplined re-entry on pullbacks into the 9/20 EMA support zone.

• ↑Q2 revenue $10.5B (+4.8% YoY) accelerated to mid-single digits
• ↑Declared 410th consecutive $0.63 dividend, yielding 0.88%
• ↓Weak profitability factors and low earnings yield pressure returns